The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1075
April 3, 2000
View Complete Issue         Table of Contents 2019 
Bexarotene (Targretin) For Cutaneous T-cell Lymphoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bexarotene (Targretin) For Cutaneous T-cell Lymphoma
April 3, 2000 (Issue: 1075)
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bexarotene (Targretin) For Cutaneous T-cell Lymphoma
Article code: 1075b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.